On Feb. 13, biotech company Invitrogen
- Revenues grew by 1.4%; the 2.7% growth in the biodiscovery division was offset by the 1% decline in the cell culture division's revenue.
- The company reported a net loss of $100 million versus a profit of about $50 million in the year-ago quarter, primarily due to merger-related impairments totaling $149 million to amortization and goodwill.
- Free cash flow declined by 26.8% because of a huge net loss and unfavorable changes on the balance sheet.
- Invitrogen has decided to sell its BioReliance business unit to Avista Capital Partners for about $210 million.
- Last year, the company repurchased 5.8 million shares for $350 million.
(Figures in millions, except per-share data)
Income Statement Highlights
Q4 2006 |
Q4 2005 |
Change |
|
---|---|---|---|
Sales |
$329.8 |
$325.3 |
1.4% |
Net Profit |
($100.2) |
$49.6 |
N/A |
EPS |
($2.08) |
$0.94 |
N/A |
Diluted Shares |
48.1 |
58.7 |
(18.0%) |
Get back to basics with a look at the income statement.
Margin Checkup
Q4 2006 |
Q4 2005 |
Change* |
|
---|---|---|---|
Gross Margin |
58.2% |
55.8% |
2.5 |
Operating Margin |
(27.0%) |
8.3% |
(35.3) |
Net Margin |
(30.4%) |
15.3% |
(45.6) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
Assets |
Q4 2006 |
Q4 2005 |
Change |
---|---|---|---|
Cash + ST Invest. |
$380.3 |
$751.9 |
(49.4%) |
Accounts Rec. |
$205.3 |
$194.9 |
5.3% |
Inventory |
$149.7 |
$136.8 |
9.5% |
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
---|---|---|---|
Accounts Payable |
$223.4 |
$244.3 |
(8.6%) |
Long-Term Debt |
$1,155.0 |
$1,386.2 |
(16.7%) |
Learn the ways of the balance sheet.
Cash Flow Highlights
2006 |
2005 |
Change |
|
---|---|---|---|
Cash From Ops. |
$235.1 |
$309.3 |
(24.0%) |
Capital Expenditures |
$61.1 |
$71.8 |
(14.9%) |
Free Cash Flow |
$174.0 |
$237.6 |
(26.8%) |
Find out why Fools always follow the money.
Related companies:
-
Techne
(NASDAQ:TECH) -
Bio-Rad Laboratories
(AMEX:BIO) -
Becton, Dickinson
(NYSE:BDX) - Stratagene ( Nasdaq: STGN)
-
Harvard Bioscience
(NASDAQ:HBIO)
Related Foolishness:
- Strong Start at Meridian Bioscience
- Banner Year for Meridian Bioscience
- Picks and Shovels of Biotechnology
A free trial to Rule Breakers gives you a chance to chat with other investors and our analysts about the technologies that will change our lives and help our portfolios.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.